ASP 5034
Alternative Names: ASP-5034Latest Information Update: 05 Nov 2023
At a glance
- Originator Astellas Pharma
- Class Antihyperglycaemics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 06 Aug 2012 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (PO)
- 01 Aug 2011 Phase I development in Type-2 diabetes mellitus is ongoing in the USA
- 12 May 2010 Phase-I clinical trials in Type-2 diabetes mellitus in USA (PO)